{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.4","value":"-0.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"The FACT HN is a patient reported outcome (PRO) measure that assesses health related quality of life in patients with head and neck cancer. It evaluates general cancer related quality of life as well as symptoms and concerns specific to head and neck cancer. The total score range is 0 - 144, with higher scores reflecting more positive perceptions across areas of well-being.\n\nA difference score from end of treatment and pre-treatment was calculated.","dispersionType":"Standard Deviation","groups":[{"description":"Amivantamab weekly for the first cycle and biweekly thereafter.\n\nAmivantamab: Patients will receive amivantamab at 1050mg weekly for the first cycle and biweekly thereafter (1400mg for patients ≥80kg).","id":"OG000","title":"Amivantamab"}],"paramType":"MEAN","populationDescription":"19 patients with evaluable inventory data","reportingStatus":"POSTED","timeFrame":"2 years","title":"Quality of Life - Measured Via FACT-HN","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"units on a scale"}